FDA approves first-line treatment for patients with non-recyctoctable hepatocellular carcinoma

Today, the U.SFood andMedicines(
FDA( fda) approved theofproducts owned by Weissa Pharmaceuticals (Lenvatinib, L), for first-line treatment for patients with non-recytoctable hepatocellular carcinoma (HCC)LenvatinibLenvatinib is an oral polykinase inhibitordrug(which selectively inhibits kinase activity of vascular endothelial growth factor (VEGF) receptors, as well as other POPKs associated with angiogenesis and cancer-causing pathways, including fibromyal growth factor (FGF) receptors, platelet-derived growth factor (PDGF) receptors, etcFebruary 2018, the main journal of the international authoritative medical journal Lancet published a heavy Phase III clinical study, the REFLECT study, published the results of clinical studies conducted in 154 research centers in 20 countries around the worldAccording to the imaging evaluation data of the third-party independent evaluation committee, the treatment of lacofinib can extend the time from 3.7 months to 8.9 months for the progression of liver cancer to 8.9 months, increase the probability of reducing or disappearing from liver cancer from 12.4% to 40.6%, and the disease control rate from 58.4% to 73.8%this approval is based on the results of an open label, multicenter, randomized, non-performance clinical phase 3trialknown as REFLECT In this clinical trial, 954 patients who were unable to remove or metastatic HCC were treated with lenvatinib or sorafenib These patients have not received any pre-treatment test results show that lenvatinib and sorafenib have achieved non-poor efficiency standard in total lifetime index compared to sorafenib The average total lifetime of the Lenvatinib group was 13.6 months, compared with 12.3 months in the control group Furthermore, the average progression-free lifetime of the lenvatinib group was 7.4 months, significantly higher than the 3.7 months in the control group (p.001) The total mitigation rate of the Lenvatinib group was also higher than that of the control group (41% to 12%, with the use of mRECIST detection (standard; 19% to 7%, and using THE RECIST 1.1 test standard) 2017 CSCO Conference (above, REFLECT study of China's leading researcher, Professor Qin Shuxuan of the Nanjing People's Liberation Army's 81st Hospital) published data on china sub-group The study included a total of 288 patients in mainland China, Taiwan and Hong Kong, which fully reflected the efficacy of Lonvastinib, which is more suitable for liver cancer patients in China The study showed that the total survival time of patients with liver cancer in China after receiving levantini treatment was significantly extended by 50%, and the advantages of treating levantini with combined hepatitis B infection were more obvious it is understood that in December last year close to the CFDA "New Deal" good, Lunvastini has been qualified for priority review approval As the first successful lying first-line target drug for liver cancer in a decade, Lonvastinib is particularly suitable for liver cancer patients in China